Description
LATS2 protein is a serine/threonine protein kinase, 1088 AA; 120 kDa; cofactor is magnesium. Subunit interacts and is phosphorylated by STK6. LATS2 binds to AR and interacts to JUB during mitosis. Complex regulates spindle apparatus organisation through gamma-tubulin recruitment to the centrosome. Protein is auto-phosphorylated and phosphorylated during Mand G1/S-phase of cell cycle; phosphorylated and activated by STK3.
Expression
Expressed at high levels in heart and skeletal muscle and at lower levels in all other tissues examined. Gene is found in cDNA libraries from the following tissue types: b-cell, bone, bone marrow, brain, cartilage, cerebrum, colon, ear, embryonic tissue, eye, foetus, gastrointestinal tract, heart, kidney, liver, lung, lymph node, lympho-reticular, mammary gland, muscle, nervous, ovary, pancreas, pancreatic islet, peripheral nervous system, placenta, pooled tissue, prostate, skin, spleen, stem cell, stomach, t-cell, testis, uncharacterized tissue, uterus, vascular.
Localisation
Cytoplasm, nucleus, spindle pole, centrosome; colocalizes with STK6 at the centrosomes during interphase, early pro-phase and cytokinesis. Migrates to spindle poles during mitosis, and to the mid-body during cytokinesis. S83 of Lats2 is a phosphorylation target of Aurora-A and the phosphorylation plays a role of the centrosomal localization of Lats2 (Toji et al., 2004) .
Function
Protein product involved in: G1/S transition of mitotic cell cycle, hormone-mediated signalling pathway; negative regulation of Cyclin-dependent protein kinase activity; protein amino acid phosphorylation; protein kinase cascade; centrosome localisation; ATP binding; Mg-ion binding, nucleotide binding, protein serine/threonine kinase activity; protein tyrosine kinase activity; transferase activity; negative regulation of androgen receptor activity. LATS2 is a tumour suppressor that plays critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. LATS2 is involved in conserved Hippo signalling pathway (Zhang et al., 2008; Hergovich et al., 2009 ). LATS2 has an essential role in the integrity of processes that govern centrosome duplication, mitotic fidelity and genomic stability (McPherson et al., 2004) . Components of the pathway bring LATS2 in contact with MST1 and MST2 kinase, which phosphorylates and activates LATS2. Functionally, pathway with LATS2 included is involved in cell proliferation, apoptosis, and cell migration. Involvement in apoptosis has been demonstrated in lung cancer cells where LATS2 has been shown to induce apoptosis through down regulation of BCL-2 and BCL-XL (BCL2L1) anti-apoptotic proteins (Ke et al., 2004) . LATS2 has been reported to inhibit cell growth by causing G1/S and/or G2/M cycle arrest (Li et al., 2003; Kamikubo et al., 2003) . LATS2 binds MDM2 and with inhibiting its E3 ligase activity activates TP53.
Position of alterations marked on the exons; length and position of the coding region described according to the exons.
In turn TP53 rapidly and selectively up-regulates LATS2 expression in G2/M cells, defining positive feedback loop. Therefore LATS2-MDM2-TP53 constitutes a novel checkpoint pathway critical for maintenance of proper chromosome number (Aylon et al., 2007) . LATS2 is also associated with Ajuba in LATS2-Ajuba complex that regulates organization of the spindle apparatus through recruitment of γ-tubulin to the centrosome (Abe et al., 2006) . In vitro over expression of LATS2 was seen to cause G1/S arrest through the inhibition of CDK2 activity (Li et al., 2003) . Complete LATS2 knock-out cells exhibit an acceleration of exit from mitosis and marked downregulation of critical mitotic regulators, proving its role in coordinating accurate cytokinesis completion, governing the stabilization of other regulators of mitosis . Study of LATS2 knockout cells and transient co-expression of LATS2, YAP and TP73 showed that LATS2 contributes to the stability of YAP2 (YAP1) and TP73, which is dependant on the kinase function leading to the conclusion that LATS2 is involved in the fate of TP73 through YAP2 (Kawahara et al., 2008) .
Mutations

Germinal
No data.
Somatic
Mutations are rare and mostly found in cancerous tissue. More frequently hypermethylation of the LATS2 promoter and or down-regulation of the expression is related to different kind of cancers (lung, breast, hepatocellular, leukaemias, testicular, astrocytomas, retinoblastoma, head and neck). When polymorphism is noted or when dbSNP entrance number is provided, alterations are listed as polymorphisms; references are those when the alteration was first published. 
Implicated in
Various cancers
Note Loss of LATS2 in mice is lethal. Knockout of the gene in mice embryonic fibroblasts induces mitotic defects, genomic instability and loss of contact inhibition (McPherson et al., 2004; Yabuta et al., 2007) . Overexpression of LATS2 inhibits tumour formation in mice, or reduces cell growth in human tumour cell lines (Yang et al., 2001; Xia et al., 2002; Li et al., 2003) and on the other hand mutations and/or reduced expression (either methylation or miRNA regulation or unknown) have been observed in variety of human cancers; leukaemia (Jimenez-Velasco et al., 2005) , astrocytomas (Jiang et al., 2006) , prostate (Powzaniuk et al., 2004) , breast (Takahashi et al., 2005) , lung , head and neck (Steinmann et al., 2009 ), retinoblastoma (Chaktaborty et al., 2007 , oesophageal (Lee et al., 2009) , hepatocellular (Chen et al., 2005) and possibly also colon (Sivarajasingham et al., 2003) cancer. Frequent LOH of the gene has been observed in breast, ovary and liver cancer (Lee et al., 1988; Sato et al., 1991; Wang and Roger, 1988) .
Breast cancer
Note
Reduced expression of LATS2 mRNA is associated with biologically aggressive phenotypes of breast cancer, indicating that the reduced function of LATS2 can lead to accelerated cell proliferation and have as a result higher incidence of distant metastases (Takahashi et al., 2005) . LATS2 mRNA levels were in 2007 discovered to be clinically useful for the prediction of response to epirubicin plus cyclophosphamide treatment in breast cancer patients (Takahashi et al., 2007) .
LATS2 (LATS, large tumor suppressor, homolog 2 (Drosophila) ) Glavač D, Stražišar M Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10) Acute lymphoblastic leukaemia Prognosis Down regulation mainly by aberrant promoter methylation of LATS2 is also associated with poor prognosis in acute lymphoblastic leukaemia (JimenezVelasco et al., 2005) .
Testicular and prostate tumours
Note In testicular germ cell tumours miRNAs (miR-372 and miR-373) were implicated in neutralization of TP53-mediated CDK inhibition, through direct inhibition of the expression of LATS2 (Voorhoeve et al., 2006) . It has been also shown that LATS2 is down regulated in human testicular cancer cells (Vorhoeve et al., 2006; Duale et al., 2007) . LATS2 functions also as negative regulator of AR (androgen receptor), which plays an essential role in the development and maintenance of the male reproductive system and in prostate cancer. It has been shown that expression of LATS2 is lower in human prostate tumours, and suggested to contribute to the development of prostate cancer through regulation AR-mediated transcription (Powzaniuk et al., 2004) .
Astrocytomas
Note Methylation of LATS2 and down regulation was detected in astrocytomas and proposed as a useful target for astrocytomas therapy by Jiang et al. (2006) .
Oesophageal squamous cell carcinoma
Note Frequent polymorphic changes but rare tumour specific mutations of the LATS2 gene were found in oesophageal squamous cell carcinoma, indicating LATS2 is inactivated in only small parts of oesophageal tumours (Ishizaki et al., 2002) .
Non-small cell lung cancer
Note Down regulation of LATS2 have been found in nonsmall cell lung cancer and mutations discovered have been related mostly to squamous lung cell carcinomas (Strazisar et al., 2009a; Strazisar et al., 2009b) .
Breakpoints
Note Data about all observed breakpoints found at the approximate/distal location of LATS2, but no mentioning of the gene itself: NCBI CancerChromosomes database: Over 500 investigations on 13q11 and over 1000 on 13q12. The Cancer genome anatomy project: 209 investigations on 13q11 found.
